Forefront Analytics, LLC Eiger Bio Pharmaceuticals, Inc. Transaction History

Forefront Analytics, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$0.89 - $2.52 $34,977 - $99,036	39,300 Added 317.47%	51,679 $46,000
Q4 2022 Feb 13, 2023	BUY	$1.02 - $7.48 $12,626 - $92,594	12,379 New	12,379 $14,000
Q2 2022 Aug 10, 2022	BUY	$4.99 - $8.96 $3,493 - $6,272	700 Added 6.47%	11,527 $73,000
Q1 2022 May 09, 2022	BUY	$3.84 - $9.74 $1,824 - $4,626	475 Added 4.59%	10,827 $87,000
Q4 2021 Feb 11, 2022	BUY	$5.12 - $8.19 $1,408 - $2,252	275 Added 2.73%	10,352 $58,000

Q3 2021 Nov 15, 2021	BUY	$6.68 - $9.1 $334 - $455	50 Added 0.5%	10,077 $68,000
Q2 2021 Aug 10, 2021	SELL	$7.82 - $9.23 $5,755 - $6,793	-736 Reduced 6.84%	10,027 $82,000
Q1 2021 May 13, 2021	BUY	$8.44 - $12.66 $90,839 - $136,259	10,763 New	10,763 $97,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $490M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Forefront Analytics, LLC, based on Form 13F filings with the SEC.

Stay updated on Forefront Analytics, LLC with notifications on news.